CSCI (cosciensbio.com) צמיחת רווח למניה השנה
COSCIENS Biopharma Inc. (CSCI) attracts scientists with academic freedom and stock options, as evidenced by the distribution of annual earnings per share changes. The value of 0.00 indicates the current yield level. Capital is generated through the exclusive distribution of orphan drugs in Latin America and Canada. Isolation from global macroeconomic fluctuations transforms the company into a resilient defensive asset with constant demand.
פילוחי מדדים פיננסיים ומדדי שוק עבור COSCIENS Biopharma Inc. (CSCI)
When selecting defensive assets, high market resilience and the possession of patents are the priorities. COSCIENS Biopharma Inc. (CSCI) ensures this stability through its exclusive drug Macrilen for the diagnosis of endocrine pathologies. The year-over-year EPS trend reflects the percentage shift in net income per share, allowing for a real-time assessment of the business's capitalization efficiency relative to the previous year.
